Post-Market Surveillance (PMS) under the EU MDR

A complete guide to designing & implementing PMS systems for medical devices

Looking for expert consulting support on your regulatory strategy? Contact us today for a free & confidential discussion about your options.

What is Post-Market Surveillance (PMS)?

Video 1: A 3 minute summary of what Post-Market Surveillance (PMS) is under the EU MDR

Post-Market Surveillance (PMS) can be defined as a structured process of monitoring the safety and performance of a medical device following its release onto the market. It involves the proactive collection and review of data relating to clinical experience with the device.

Effective Post-Market Surveillance requires a combination of processes and systems that work together to develop a robust ‘picture’ of how a medical device is performing in real-world use following its commercial release.

The MDR builds upon previous requirements for PMS systems in medical devices. It requires that a Post-Market Surveillance framework is in place for all medical devices, using a design that is proportionate to risk class and appropriate for device type.

What are the MDR requirements for Post-Market Surveillance?

Manufacturers are required to establish, document, implement, maintain, update and improve their Post-Market Surveillance systems continuously
Fig 1: The requirements for Post-Market Surveillance (PMS)

MDR Article 83 outlines the requirements for Post-Market Surveillance systems under the new regulatory framework. Every manufacturer is required to plan, establish, document, implement, maintain and update a PMS system for every medical device. The system must be designed and documented in a PMS plan (detailed below) and then constantly updated according to a structured assessment of how well it is working and ongoing analysis of the data it has yielded.

MDR Article 83 requires that data generated by Post-Market Surveillance systems is used in specific ways; in particular it should be used to:

  • Update the benefit-risk profile of the device through contributing data about the frequency and severity of device-related harms
  • Feed improvements to Risk Management processes
  • Update device design, Instructions For Use (IFU) and device labels to optimise device safety and performance during use
  • Form a core component of updating the Clinical Evaluation of the device
  • To identify needs for Preventive And Corrective Actions (PACAs) or Field Safety Corrective Actions (FSCAs)

How does an effective Post-Market Surveillance system monitor medical device safety?

The continuous clinical evidence collection process in Post-Market Clinical Follow-up
Fig 2: The continuous clinical evidence collection process in Post-Market Clinical Follow-up (PMCF)

A well-designed PMS system will monitor the safety and performance of a medical device through two complementary domains:

  • Post-Market Clinical Follow-up (PMCF) that involves the design and conduct of clinical studies to proactively and continually assess device safety and performance
  • Vigilance systems that monitor and respond to complaints, adverse events, media reports, serious incidents and FSCAs

Vigilance systems can be thought of as an “ear to the ground” for any potential safety or performance concerns relating to the device. Although rare in practice, it is at least theoretically possible for vigilance systems to return no data. On the other hand, PMCF involves the continuous collection of clinical data throughout the entire clinical lifetime of the device, generating Real World Evidence (RWE) on safety and performance. In contrast to vigilance, Post-Market Clinical Follow-up will always return some data by virtue of design.

Post-Market Surveillance systems that incorporate both arms of data collection are more robust and will more closely align with MDR requirements.

What documents must be produced in relation to MDR PMS systems?

PMS in the MDR

Guidance on Post-Market Surveillance systems in the MDR, with a focus on requirements for medical device manufacturers

Free download — PMS in the MDR

MDR Annex III provides useful details about what technical documents must be produced in relation to Post-Market Surveillance.

All MDR PMS systems require a PMS Plan that describes in detail how the system will collect and analyse safety and performance data. A well-written PMS Plan will account for using data from a wide range of different sources including:

  • Serious incidents
  • Field Safety Corrective Actions (FSCAs)
  • Complaints
  • Databases and/or registries
  • Feedback and complaints
Where Post-Market Surveillance fits into the medical device regulation environment
Fig 3: Where Post-Market Surveillance fits into the medical device regulation environment

MDR Annex III outlines rules for constructing the PMS Plan. As a minimum the PMS plan should contain the following:

  • A documented process to collect information from the identified data sources
  • A description of methods that will be used to assess and interpret collected data
  • An explanation of the rationale used during risk analysis
  • Detail of methods for collecting and investigating complaints and analysing trends
  • Procedures for communicating with competent authorities and notified bodies
  • Methods for tracing devices following product complaints or adverse events

The output of PMS activities must be collated in a PMS output report. The format of this report varies according to the device’s risk class:

  • For Class I devices a comparatively simple PMS Report is required that simply summarises outcomes from PMS activities relating to the device.
  • For all other device classes a more detailed Periodic Safety Update Report (PSUR) must be produced with a periodicity that varies according to risk class (at least annually for Class III).

What are MedDev 2.12/1 Rev 8 and MedDev 2.12/2 rev 2? How do they relate to PMS under the MDR?

The European Commission produces a range of guidance documents, known as MedDev guidelines, in relation to medical device regulation. MedDev guidelines are not legally binding but are a very useful source of information when developing PMS systems and other aspects of medical device regulation.

MedDev 2.12/1 Rev 8 provides guidance on medical device vigilance systems and MedDev 2.12/2 rev 2 details guidelines for PMCF. Although neither has yet been updated (as of December 2020) to reflect changes introduced by the MDR, they are still extremely useful documents. A combination of familiarity with the content of the MedDev guidelines along with the content of relevant sections of the MDR will form the basis of an ability to develop an MDR compliant PMS system.

Do you need help with your regulatory strategy?

Talk to us